biote (NASDAQ:BTMD) Releases Earnings Results, Misses Expectations By $0.26 EPS

biote (NASDAQ:BTMD) posted its quarterly earnings results on Wednesday. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.26), FiscalAI reports. The business had revenue of $44.23 million for the quarter, compared to analyst estimates of $46.12 million. biote had a negative return on equity of 25.72% and a net margin of 8.29%.

Here are the key takeaways from biote’s conference call:

• Negative Sentiment: Second-quarter revenue fell 9.5% to $44.2 million, while procedure revenue declined 13.9% to $30.3 million, pressured by the voluntary pellet recall, supply constraints, clinic attrition, and slower new-clinic productivity.
• Negative Sentiment: Biote lowered its 2026 outlook to revenue above $175 million and adjusted EBITDA above $25 million, compared with prior guidance of more than $190 million and $38 million, respectively; year-over-year procedure revenue is now expected to remain negative in the second half.
• Positive Sentiment: Management said Asteria Health’s supply continuity and inventory levels have normalized, with a second production shift added; reduced reliance on higher-cost third-party pellets is expected to improve gross margins beginning in the third quarter.
• Neutral Sentiment: The company is entering a second strategic phase focused on clinic retention, practitioner engagement, sales-force productivity, and faster new-clinic ramp-up, while also evaluating disciplined inorganic opportunities that could expand its market footprint.
• Positive Sentiment: Dietary-supplement revenue increased 5.7% to $11.4 million, supported by e-commerce and strong adoption among existing clinicians, and is expected to grow at a mid- to high-single-digit rate for 2026; recently resolved legal matters should also reduce future expenses.

biote Price Performance

Shares of BTMD stock traded down $0.46 during trading hours on Thursday, reaching $1.80. 112,473 shares of the stock were exchanged, compared to its average volume of 246,332. biote has a 12-month low of $1.27 and a 12-month high of $3.62. The business’s fifty day moving average is $2.22 and its two-hundred day moving average is $2.05. The firm has a market capitalization of $67.79 million, a P/E ratio of 4.03 and a beta of 1.64.

Analysts Set New Price Targets

BTMD has been the topic of several recent research reports. Weiss Ratings raised shares of biote from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, May 28th. Truist Financial raised shares of biote to a “strong-buy” rating in a research note on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $2.75.

Institutional Investors Weigh In On biote

Institutional investors and hedge funds have recently made changes to their positions in the business. LPL Financial LLC purchased a new stake in shares of biote in the fourth quarter valued at approximately $32,000. AQR Capital Management LLC acquired a new position in biote in the first quarter worth about $43,000. Jane Street Group LLC acquired a new position in biote in the second quarter worth $53,000. Quadrature Capital Ltd bought a new position in biote during the 4th quarter worth $38,000. Finally, Millennium Management LLC acquired a new stake in biote in the 4th quarter valued at approximately $40,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.